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INTRODUCTION 
 Ulcerative colitis (UC) is a chronic inflammatory bowel disorder that affects the 
colonic mucosa causing ulceration and leading to chronic blood and mucus diarrhoea. 
Although generally believed to be an immunological disorder, several decades of 
research have not unearthed the cause of UC. In the last seven years, genetically 
determined disorders of innate immunity have been identified as the cause of Crohn’s 
disease, the other major inflammatory bowel disorder. UC is different from Crohn’s 
disease in affecting only the mucosa and that too only in the large intestine. It is not clear 
whether it occurs in reaction to bacteria that exist within the lumen of the bowel. The 
large intestine is host to trillions of bacteria, and it is likely that the colonic mucosa has 
mechanisms to keep these microorganisms at bay and to maintain integrity of the 
mucosal barrier. It is conceivable that UC results from the breakdown of these 
mechanisms. 
 The innate immune system of the gut perceives pathogenic microorganisms 
through conserved molecular patterns (pathogen associated molecular patterns). Various 
effector molecules are synthesized and released in response to recognition of these 
pathogen associated patterns. The defensins are effector molecules of the innate immune 
system which function as anti-microbial peptides against pathogenic microbes. Reduced 
production of alpha-defensin by Paneth cells in the ileum is noted in patients with 
Crohn’s disease. On the other hand, there are reports that mRNA for beta-defensins is up 
regulated in epithelial cells and colonic mucosal plasma cells in patients with UC, and 
that such levels return to normal with therapy. While upregulation of beta defensin 
mRNA may potentially be secondary to increased exposure to luminal bacteria, it is also 
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known that there may be variations in gene number for beta-defensins. This is a 
phenomenon known as copy number polymorphism.  Defensin expression may be related 
to variation in the copy numbers of the defensin gene, since such variation is known to 
occur in man. This study was undertaken to determine whether patients with ulcerative 
colitis have variations in human beta-defensin gene copy numbers in comparison to 
control volunteers. 
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REVIEW OF THE LITERATURE 
Ulcerative colitis (colitis ulcerosa, UC) is a chronic inflammatory bowel disorder 
(IBD) that affects the colon inducing characteristic ulcers.  It affects the rectum and 
extends proximally along a variable length of colon.  The main symptom of active 
disease is usually gradual onset of diarrhea mixed with blood. UC also affects many parts 
of the body outside the intestine.  It is an intermittent disease with periods of exacerbation 
and periods of disease remission.  Although the symptoms of ulcerative colitis can 
sometimes diminish spontaneously, the disease usually requires treatment to go into 
remission. It can usually be well controlled with medications.  Most people live normal 
and productive lives.  Control of the disease includes long term medical treatment and 
regular monitoring of complications. 
History 
1859: Dr. Samuel Wilks first described this disease as “Idiopathic Colitis”. He 
recognized disease distinct from bacillary dysentery. He reported the pathologic finding 
of dilated and thinned colon, and noted severe universal inflammation in a patient with 
this condition. 
1905: Lockhart–Mummery, who invented the Electric sigmoidoscope, named features as 
“sigmoiditis”. 
1909: Sir Arthur Hurst gave more complete description of ulcerative colitis. He described 
sigmoidoscopic appearances and differentiation from bacillary dysentery. 
1913: Brown proposed ileostomy to rest the bowel with fecal diversion and allow it to 
heal. 
1926: Geoffrey Bourney first reported ulcerative colitis in children 
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1940:  Sulphasalazine was introduced as an effective drug against ulcerative colitis 
1945:  Dennis in Minneapolis recommended colectomy at the same time as ileostomy 
1964:  Dick et al conducted controlled trial and proved the efficacy of sulphasalazine 
1964: Ehrenpreis and Ericson advocated colectomy early in the course of the disease 
1950: Bryan Brooke Introduced end ileostomy 
1950: Truelove and Witts proved steroids as effective medical treatment of UC 
Epidemiology 
The incidence and prevalence of UC varies with geographic location and 
ethnicity.  With available epidemiological data; the areas with highest rates of reported 
incidence and prevalence of ulcerative colitis include North America, England, North 
Europe and Australia. In North America the incidence rates range from 6.0 to 14.3 cases 
per 100,000 person years and the prevalence ranges from 37-246 cases per 100,000 
persons. In Europe 12 the incidence rates range from 1.5 to 20.3 cases per 100,000 person 
years and the prevalence ranges from 21-243 cases per 100,000 person years. 
There is a marked ethnic variation in the incidence of ulcerative colitis. One 
ethnic group with high incidence of this disease is the Jewish population.  Incidence of 
ulcerative colitis in Jews is several folds higher than in the non-Jewish population. In 
United States it is 13 cases /100,000 in Jews compared to 3.8/100,000 in non Jews 
(13).Ulcerative colitis was traditionally considered uncommon in blacks. However studies 
in the late 1970s revealed incidence rates were comparable between whites and 
nonwhites in US. An increased incidence has been observed among blacks in South 
Africa, but still remains lower than that for South African whites (14).Ulcerative colitis in 
Asia is less common than in Western countries. The prevalence and annual incidence 
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rates for ulcerative colitis in Japan have remained relatively stable at 5.5 cases /100,000 
and 0.36 to 0.5 cases/10,000 person respectively.(15) The prevalence of ulcerative colitis 
in Indian has been reported to be substantially lower than among Europeans(16) However, 
South Asian immigrants in England are more likely to have ulcerative colitis than 
European natives(17).This changing epidemiology with immigrant population from low 
risk to high risk geographic region supports the concept of environmental influence on 
disease development(18). 
           Ulcerative colitis can present at all ages although diagnosis below 5 years and 
above 75years is uncommon,  The peak incidence of ulcerative colitis occurs in the 2nd 
and 3rd decades of life and 2nd peak between 60—70years. There is no gender difference 
at all ages (21). Ulcerative colitis is more common in industrialized than in underdeveloped 
countries, among urban than rural population, higher socio economic stratum than low. 
These observations support the notion that environmental factors influence the 
development of ulcerative colitis. 
Temporal influences: 
There is a progressive increase in rates of ulcerative colitis incidence in last four 
decades, which was reported in studies in Europe (19) and Sweden (20).  It has been 
suggested that this trend reflects a parallel temporal change in some life style 
(environmental factors with increased exposure to an unidentified disease triggers (or) 
because of increased access to diagnostic technologies like fiberoptic endoscopy. 
Environmental Risk Factors: 
Only a few environmental exposures are widely accepted as altering an individual’s risk 
of developing ulcerative colitis, as described below: 
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Smoking: 
 It is the best and most consistently documented environmental factor associated 
with ulcerative colitis and has a protective effect on the development of the disease. 
Harries et al (22) in1982 reported the lower than expected prevalence of smoking among 
patients with ulcerative colitis.  Harries et al did a case control study (23) comparing the 
smoking habits of patients with ulcerative colitis and healthy control groups.  They found  
1. Current smokers are under represented among  those with ulcerative colitis 
2. Much of this under representation is due to a higher proportion of never smokers 
3. Patients with ulcerative colitis who had smoked usually had quit before the onset 
of their disease. 
 Calkim (24) by metaanalysis found that life time non smokers were 2.9 times (95% 
CI, 2.6-3.2) more likely to develop ulcerative colitis than current smokers. Former 
smoker were also demonstrated to be at a higher risk compared with life time non-
smokers (OR1.7).  They also found  
 1)  A dose response association with higher levels of smoking being 
associated with a lower risk of disease and  
 2)  A clustering of disease onset shortly after smoking cessation.  Boyko et al 
(25) found current smokers had lower hospitalization rates than non smokers. Smoking has 
been shown to effect the immune system and inflammatory cascades, colonic mucus, 
intestinal permeability and circulating plasma cortisol concentration (26).  
Oral Contraceptives: 
Godet et al (27) did a meta analysis which showed oral contraceptive use was 
associated with a risk of 1.29 (95% CI, 0.94-1.77), but the authors did not find any 
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evidence of dose response relationship. A population based case control study in 
Washington state by Boyko et al (28) found a relative risk of 2 (95%CI, 1.2 – 3.3).In 
ulcerative colitis there was no difference in risk with oral contraceptive use but a 
difference was seen based on estrogen dose. A cohort study(29) found that oral 
contraceptive use was an independent risk factor for recurrence following medical (or) 
surgical induction of remission, with a risk of 3 (95% CI, 1.5-5.9).A clear pathogenic 
mechanism for contraceptives in the development of IBD has not been  defined.  
Events in childhood: Infection, hygiene, and breast feeding: 
 Epidemiological studies have suggested a role for perinatal or early childhood 
events in the etiology of IBD. Early life events could also provide an explanation for 
geographic differences in disease incidence. Specific and non specific exposures have 
been studied to explain these epidemiological observations. Nonspecific exposures 
include early weaning, hygiene, gastroenteritis and other nonspecific infection. Specific 
exposures include measles, vaccines, appendicectomy, passive smoking and dairy 
products. Studying the role of early childhood events is clearly challenging especially 
since measuring exposure status usually relies on a subjects recall of early life events. 
Acheson and Truelove (30) in 1961 reported patients with ulcerative colitis likely 
to have been weaned early compared with healthy control.  In 1979, Whorwell et al 
confirmed a higher prevalence of early weaning in subjects with ulcerative colitis. 
Rigars et al found a relative risk comparing those who were breastfeed for less 
than 5 months to those who were never breast feed was 0.7for both ulcerative and CD (32). 
Breast feeding is known to provide immunological protection to the newborn and is 
important in the development of the intestinal mucosal barrier function. 
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Appendectomy:  
Gilat et al (33) noted a lower than expected rate of appendectomy in patients 
diagnosed with ulcerative colitis in childhood. Rutgerts (34) reported that only one of 174 
ulcerative colitis patients had undergone an appendectomy before the onset of their 
ulcerative colitis, a rate much lower than that seen in controls. A meta-analysis by 
Koutrarbakin et al (35) found that appendectomy reduced the risk of ulcerative colitis by 
69%  (95% CI 62% - 75%). Anderson et al (36) performed a large cohort study using 
Swedish population-based health registries and found negative association between 
appendectomy and the subsequent development of ulcerative colitis but only for those 
who underwent appendectomy for inflammatory conditions (appendicitis and mesenteric 
lymphadenitis) but no protective effect in those who underwent appendectomy for 
nonspecific abdominal pain and also found to be useful only if performed before age 20 
years. Anderson et al argue that their findings suggest that it is not the appendectomy that 
is protective but the inflammatory process that led to the appendectomy possibly 
reflecting a predisposition to a type-1 helper T-cell inflammatory response rather than the 
type 2 response. 
Etiology And Pathogenesis: 
The etiology of ulcerative colitis is presently unknown but is likely multi-
factorial.  It involves complete interaction of three elements:  
1. Genetic susceptibility 
2. Host immunity and 
3. Environmental factors. 
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  Dysregulation of the enteric immune response in genetically predisposed 
individuals leads to the development of acute and chronic inflammation and the 
pathological features of mucosal damage.  The specific inciting antigens for the 
inflammatory process have yet to be identified, but several sources have been suggested 
including pathogenic and commensal  micro organisms, metabolic by- products of these 
agents and normal epithelial structures. 
Genetics: 
          Genetic factors have been limited to the development of ulcerative colitis.  Family 
history is one of the most important risk factors for development of the disease. Kirsner 
& Spencer in 1963 first observed familial occurrence of disease (39). 10-20% of the   
patients have at least one other affected family member.  This familial association occurs 
in first degree relatives. North American and European studies have found a relative risk 
of 7-17 in the siblings of an individual with ulcerative colitis.  Parent’s off-springs and 
second degree relatives appear to be at lower risk for development of ulcerative colitis 
than all the first degree relatives. Parent sibling concordance is more common in United 
States but disease concordance is mostly between siblings in United Kingdom. 
Jewish population which has a higher incidence of IBD has greater familial 
association.  The life time risk of development is three fold higher among first degree 
relations of Jewish patients (37).  A similar increase in risk also has been observed in 
relatives of patients with early onset of disease.  Clinical characteristics of familial 
disease also have shown that onset of disease in a child is noted at a much earlier age than 
in the affected parent, but there is a high degree of concordance between affected siblings 
for age of onset. 
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For all affected first degree relatives with in a family there is a high concordance 
for type of disease (ulcerative colitis vs Crohn’s disease), extent of disease and 
occurrence of extra intestinal manifestations. Twin studies have given strongest evidence 
of genetic influence for ulcerative colitis.  Large European twin pair studies showed 
approximately 6-10% of monozygotic twin pairs had concordant ulcerative colitis 
compared with 0 to 5% of diagnostic twin pairs (40 – 42). Linkage studies have suggested 
that there were susceptibility genes for ulcerative colitis at chromosomes 2, 3, 6, 7 and 12 
(43, 44). IBD 2 Locus on chromatic 12 appears to have the strongest linkage (45) 
demonstrated in studies involving large number of families with ulcerative colitis (45). 
The MDRI gene product P.glycoprotein is highly expressed in intestinal epithelial 
cells and serves an important barrier function against xenobiotics.  Animals deficient for 
the MDRIa gene develop a spontaneous colitis resembling ulcerative colitis (46). There are 
also genes that appear to influence disease behavior independently of susceptibility 
genes.  The following positive HLA associations have been found in various studies. 
• Ulcerative colitis in the Japanese population and HLA-B5 (or the HLA-B5 
subtype, HLA-B52 (47). 
• Ulcerative colitis in the Israel: Jewish population and HLA-35 (48) 
• Ulcerative colitis and HLA –DR2 (particularly the molecularly –
determined DRB1* 1502 allele in Japanese and Jewish populations (49) 
There also are genes that appear to influence disease behavior independently of 
susceptibility genes. The best studied of these are the human leukocyte antigen (HLA) 
alleles. One allele of HLA-DR2 (DRB1*1502) appears to be involved in disease 
susceptibility in Japanese and Jewish populations. Several centers have reported an 
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association between severe disease and a rare allele of HLA-DR1 (DRB1*0103). In some 
studies, the HLA-DR3, DQ2 haplotype is associated with extensive colitis, especially 
among women. Among the Jewish population, the peri-nuclear antineutrophil antibody 
(pANCA) is a marker for the DRB*1502 allele of HLA-DR2, but in non-Jewish whites, 
this antibody is associated with the HLA-DR3 DQ2-tumor necrosis factor (TNF)-α2 
haplotype. 
Immunopathogenesis: 
The prevailing theory of the pathogenesis of UC emphasizes the role of the 
enteric immune response. The physiologic state of the intestine is one of constant low-
grade inflammation in response to environmental stimuli such as bacterial products or 
endogenous factors. Breaches in this well-regulated mucosal immune system lead to the 
chronic uncontrolled mucosal inflammation observed in UC. In this regard, immunologic 
mechanisms in the pathogenesis of UC involve both humoral and cell-mediated 
responses. 
Humoral Immunity 
Histological examination of the inflamed colon indicates a marked increase in the 
number of plasma cells. This increase is not uniform among cells producing different 
classes of immunoglobulins. The largest proportional increase occurs in IgG synthesis, 
which has the highest pathogenic potential among antibody classes. The increase in IgG 
synthesis in UC is most pronounced in the IgG1 and IgG3 subclasses (51, 52). 
The increased IgG synthesis in ulcerative colitis may represent polyclonal 
stimulation; however, patients with UC frequently have circulating antibodies to dietary, 
bacterial, and self-antigens that are mostly of the IgG isotope, usually the IgG1 subclass. 
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Many of these antibodies are thought to be epiphenomena because the serum antibody 
titers do not correlate with clinical parameters. Nevertheless, the known cross-reaction 
between enterobacterial antigens and colonic epithelial epitopes may be an important 
triggering event, even though, later in the course of the disease, the serum antibody titer 
to either the bacterial or the colonic antigen may be unimportant. 
UC is an autoimmune disease. This belief is supported by its increased association 
with other autoimmune disorders, including thyroid disease, diabetes, and pernicious 
anemia (53).  Patients with UC have varying levels of autoantibodies to lymphocytes, 
ribonucleic acid, smooth muscle, gastric parietal cell, and thyroid antibodies; these are 
neither tissue nor disease specific. The best characterized intestinal auto antigen is an 
epithelial antigen of 40-kd size found in normal colonic epithelium(53). This auto antigen 
is recognized by IgG eluted from the inflamed colonic mucosa of patients with UC and is 
a component of the tropomyosin family of cytoskeleton proteins(54). This autoantibody 
has the potential to activate complement in vivo, but direct evidence of antibody-induced 
cytotoxicity has not been observed. The antibody response to this 40-kd protein appears 
to be unique to UC.  
pANCA is present in 60% to 85% of patients with UC(55,56). It is synthesized 
within the lamina propria and is of the IgG1 subclass. The antigen to which the pANCA is 
directed has not yet been determined with certainty. Recent evidence suggests that the 
antigen is a 50-kd nuclear envelope protein that is specific to myeloid cells (57). The 
pathogenic relevance of pANCA in UC is unknown. It may serve as a potential marker of 
susceptibility and genetically distinct subsets of UC. pANCA may be associated with a 
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more aggressive disease course(58) and the development of pouchitis following ileal 
pouch-anal anastomosis (IPAA) in patients with UC(59). 
Cellular Immunity  
                 Immune dysregulation in UC also involves cell-mediated immunity. In patients 
with UC, the absolute number of IELs is normal or reduced. Most of these cells are CD8+ 
cells, and the function of IELs has not been well characterized. It has been suggested that 
they are cytotoxicity and also may be active in suppressing local immune response (60). In 
patients with UC, the proportion of IELs using the γδ T cell receptor may increase. 
However, the function and significance of γδ T cells are unknown. Studies have 
suggested that T cell receptor repertoire is altered in active IBD (61) .Nonspecific cellular 
immunity also is altered. In patients with active disease, there is an overproduction of 
circulating monocytes as well as mucosal macrophages (62). The inflamed mucosa of 
patients with UC also exhibits infiltration of substantial numbers of granulocytes. 
Epithelial Cells  
Intestinal epithelial cells serve barrier functions and play a role in enteric 
immunity. Colonocytes express class II antigens and can function as antigen-presenting 
cells (63). In addition, they also express cytokine receptors, secrete various cytokines and 
chemokines, and express leukocyte adhesion molecules (64, 65, and 66). Thus abnormalities in 
colonic epithelial cells can contribute to the development of UC. Patients with UC have 
an increased turnover rate of colonic epithelium (67) and other abnormalities of epithelial 
cells include a reduced metabolism of short-chain fatty acids, especially butyrate, 
abnormal membrane permeability, (68) and altered composition of glycoprotein mucus 
produced by the colonic epithelium (69).  
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Consequences of Immune Activation  
Activation of macrophages, lymphocytes, and colonic epithelial cells leads to the 
release of a variety of cytokines and mediators that further amplify the immune and 
inflammatory response of UC and result in tissue damage. Based on the cytokines they 
produce, CD4+ T cells have been divided into two major immune phenotypes: T helper 1 
(Th1) and T helper 2 (Th2). The Th2 response is characterized by the production of 
cytokines IL-4, IL-5, and IL-10, which amplify the humoral immune response. Both Th1 
and Th2 pathways can be regulated by unique regulatory T cells (Th3, T regulatory 1) 
subsets that produce IL-10 and transforming growth factor-β and down-regulate 
inflammation (70). Macrophages in the inflamed colon in patients with active UC 
synthesize IL-1β, TNF, and IL-6, whereas lamina propria T cells probably produce IL-2 
and IFN-γ. This immune response can be up-regulated further by presentation of antigen 
to CD4+ lymphocytes by colonic epithelial cells that express HLA class II antigens (63). 
Release of these cytokines also may lead to other abnormalities seen in UC, such as 
increased epithelial cell permeability and collagen synthesis. Alteration of endothelium 
by a variety of cytokines may result in local ischemia. Increased expression of endothelial 
adhesion molecules in response to inflammatory mediators recruits circulating 
granulocytes and monocytes to the inflamed tissues, thus further perpetuating the 
inflammatory response. Mucosal concentrations of many mediators have been shown to 
be elevated in patients with active UC, including leukotrienes, thromboxane, platelet-
activating factor, nitric oxide, and reactive oxygen metabolites(71) These mediators, which 
are mostly released from active macrophages and neutrophils, contribute to inflammation 
and mucosal injury, altered epithelial cell permeability,  thereby further contributing to 
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diarrhea. Diarrhea in UC also is caused by complement activation and the release of 
kinins and other inflammatory mediators from mast cells and eosinophils. 
Pathology  
45% of patients with UC have disease limited to the recto sigmoid, 35% have 
disease extending beyond the sigmoid but not involving the entire colon, and 20% of 
patients have pan colitis (72).  UC starts most severe distally and progressively less severe 
more proximally, continuous and symmetrical involvement is the hallmark of UC. 75% 
of patients with left-sided UC may have appendiceal inflammation and patchy 
inflammation in the cecum (73) resembling the skip pattern characteristic of Crohn's 
disease.  
Macroscopically: the mucosa in UC appears hyperemic, edematous, and granular 
in mild disease. As disease progresses, the mucosa becomes hemorrhagic with visible 
punctate ulcers. These ulcers may enlarge and extend into the lamina propria. They often 
are irregular with overhanging edges or may be linear along the line of the teniae coli. 
Epithelial regeneration with recurrent attacks results in the formation of pseudopolyps; 
Long-standing disease can cause atrophic and featureless colonic mucosa, associated with 
shortening and narrowing of the colon.  
Microscopically: the early stage of UC is marked by edema of the lamina propria 
and congestion of capillaries and venules, often with extravasations of red blood cells. 
This is followed by an acute inflammatory cell infiltrate of neutrophils, lymphocytes, 
plasma cells, and macrophages. There also may be increased numbers of eosinophils and 
mast cells. Neutrophilic infiltration of colonic crypts gives rise to cryptitis and ultimately 
to crypt abscess with Neutrophilic accumulations in the crypt lumen. This migration of 
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neutrophils from the circulation into the lamina propria occurs in response to a variety of 
chemo attractants, including chemo tactic peptides of colonic bacteria, IL-8, activated 
complement, platelet-activating factor, and leukotriene B4. The cryptitis is associated 
with discharge of mucus from goblet cells and increased epithelial cell turnover. 
Inflammation in UC characteristically is confined to the mucosa. The inflammatory 
changes typically end at the luminal aspect of the muscularis mucosa. With increasing 
inflammation, however, the surface epithelial cells become flattened and eventually 
ulcerate. Deep ulceration may undermine the surrounding epithelium.  
During the healing phase of UC, the inflammatory infiltrate subsides and epithelial 
regeneration takes place. Epithelial cells undergoing regenerative changes become 
cuboidal with eccentric, large nuclei, and prominent nucleoli. These features may be 
confused with dysplasia.  
A classic histological feature of chronic quiescent UC is crypt architectural 
distortion or actual dropout of glands. Architectural changes include branching or bifid 
glands, wide separation among glands, and shortened glands that do not extend down to 
the muscularis mucosa. Whereas architectural alteration is a prominent feature of chronic 
quiescent UC, the histologic abnormalities may revert to normal after mild flares in the 
early course of disease. 
 Most of these findings are not specific for UC. Histologic severity of 
inflammation does not necessarily correlate with clinical disease activity in patients with 
UC and patients may be relatively symptom free, while histology reveals significant 
inflammation. 
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Clinical Features  
Patients with UC may present with a variety of symptoms. Bloody diarrhoea 
(96%) is the cardinal feature of acute ulcerativecolitis, which in most patients runs a 
clinical course characterized by unpredictable relapses interspersed with periods of 
remission. Other common symptoms include passage of mucus, tenesmus, urgency, and 
abdominal pain (mild to moderate in 55%) (77). In more severe cases, fever and weight 
loss (>5 kg in 12%) (78) may be prominent. 
The symptom complex tends to differ according to the extent of disease (74) 
Patients with proctitis often have  tenesmus, urgency, mucus, and bleeding, whereas 
patients with extensive colitis may have more diarrhea, weight loss, fever, clinically 
significant blood loss, and abdominal pain.  
The onset of UC typically is slow and insidious. The median interval between the 
onset of symptoms and diagnosis of UC is approximately 9 months (75). A paper by 
Felicity Edwards and Truelove et al (76) observed the duration of symptoms before first 
presentation was <1month in 19.6 % , 1-6 months in 58.4% and 22% in 6-12months . 
Age of onset was <20 yrs in 10 %, 20 – 59yrs in 72.8% and >60yrs in 17.2%. The median 
decade of onset was 30 – 39 yrs (26.9%) and there was no second peak in older age, 
although 3.2% presented over the age of 80.  
Symptoms  
Rectal Bleeding  
Rectal bleeding is common in UC. The characteristic of the bleeding is 
determined by the location of the disease. Patients with proctitis usually complain of 
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passing fresh blood, either separately from the stool or streaked on the surface of a 
normal or hard stool (79). Patients with ulcerative proctitis often pass a mixture of blood 
and mucus and may even be incontinent. Patients with proctitis also often complain of the 
frequent and urgent need to defecate, only to pass small quantities of blood and mucus 
without fecal matter. 
When the disease extends proximal to the rectum, blood usually is mixed with 
stool or there may be grossly bloody diarrhea. When the disease activity is severe, 
patients pass liquid stool containing blood, pus, and fecal matter.  
Diarrhea  
Diarrhea is common but not always present in patients with UC. Up to 30% of 
patients with proctitis or proctosigmoiditis may complain of constipation and hard stools 
(79). Most patients with active disease complain of frequent passage of loose or liquid 
stools and may have nocturnal diarrhea. Fecal urgency, sensation of incomplete 
evacuation, and fecal incontinence also are common, especially when the rectum is 
severely inflamed. Diarrhea in this setting often is accompanied by passage of large 
quantities of mucus, blood, and pus. 
The Pathophisiology of the diarrhea in UC involves several mechanisms, 1) 
failure to absorb salt and water is perhaps the predominant factor(80) ,This failure results 
from reduced Na+/K+, ATPase pump activity, increased mucosal permeability, and 
altered membrane phospholipids. Urgency and tenesmus, which are common symptoms 
when the rectum is inflamed, are caused by poor compliance and loss of the reservoir 
capacity of the inflamed rectum (81) with severe inflammation, the urgency can be 
sufficiently acute as to cause incontinence. 
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Colonic motility is altered by inflammation, and there is rapid transit through the 
inflamed colon. With left-sided disease, distal transit is rapid, but there is actual slowing 
of proximal transit, (82) which may help explain the constipation that is commonly seen in 
patients with distal colitis. Prolonged transit times in the small intestine also occur in the 
presence of active colonic inflammation (82). 
Abdominal Pain  
Many patients with UC complain of abdominal pain with active disease, but pain 
generally is not a prominent symptom. Patients may experience vague lower abdominal 
discomfort, an ache in the left iliac fossa, or intermittent abdominal cramping preceding 
bowel movements and often persisting transiently after defecation. Severe cramping and 
abdominal pain can occur in association with severe attacks of the disease. 
Pathophisiology of pain is not clear, probably related to the increased tension 
within the inflamed colonic wall during muscular contraction. Patients with active 
proctitis also frequently complain of tenesmus and urgency associated with painful 
straining and passage of mucus and blood with only scanty stools. 
Other Symptoms  
Disease of moderate or severe activity often may be associated with systemic 
symptoms. Patients may develop anorexia and nausea .Protein loss through inflamed 
mucosa, hyper catabolism, and down-regulation of albumin synthesis caused by the 
inflammation, account for weight loss and hypoalbuminemia. Fever usually accompanies 
severe attacks. A few patients may present with extra intestinal manifestations, such as 
acute arthropathy, episcleritis, and erythema nodosum. These manifestations typically 
parallel the activity of colitis. 
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Signs  
Patients with mild or even moderately severe disease exhibit few abnormal 
physical signs. They are usually well nourished and well appearing and show no signs of 
chronic disease. Indeed, these patients can appear deceptively well. Weight should 
always be recorded, and, for children and adolescents, both height and weight should be 
plotted on developmental growth charts. The affected portion of the colon may be tender 
on abdominal palpation, but this generally is mild and not associated with rebound or 
guarding. Bowel sounds are normal. Digital rectal examination also is frequently normal, 
but the rectal mucosa may feel “velvety” and edematous; the anal canal may be tender; 
and there may be blood on withdrawal of the examining finger. 
Patients with severe attacks also may appear well, but most are ill with 
tachycardia, fever, orthostasis, and weight loss. The abdomen typically is soft with only 
mild tenderness over the diseased segment. Abdominal tenderness may become diffuse 
and moderate with more severe disease. Bowel sounds may be normal or hyperactive but 
diminish with progressive disease. In fulminant colitis, the abdomen often becomes 
distended and firm, with absent bowel sounds and signs of peritoneal inflammation. 
There may be aphthoid ulceration of the oral mucosa. Clubbing of the fingernails is a 
frequent manifestation of chronic disease. Peripheral edema may occur secondary to 
hypoalbuminemia. Minor perianal disease may be present but is never as severe as is seen 
in patients with Crohn's disease. Signs of extraintestinal manifestations also may be 
present. 
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Extra Intestinal Manifestations 
 These extra intestinal manifestations may affect virtually every organ system, but 
the most commonly involved organs are the skin, eyes, mouth, joints, and liver .These 
extra intestinal complications are often classified by their relations to the activity of the 
colitis, but they may occur before, during, or following exacerbations of bowel disease. 
Manifestations that parallel disease activity usually improve on treatment of the colitis. 
Common Extra Intestinal Manifestations of Ulcerative Colitis  
System Manifestations 
Peripheral arthropathy 
Ankylosing spondylitis 
Sacroiliitis 
Osteopenia 
Osteoporosis 
Osteomalacia 
Musculoskeletal 
Osteonecrosis 
Erythema nodosum 
Pyoderma gangrenosum 
Oral ulcerations 
Angular stomatitis 
Aphthous stomatitis 
Pyostomatitis vegetans 
Psoriasis 
Dermatologic 
Sweet's syndrome (acute febrile neutrophilic dermatosis) 
Uveitis/iritis 
Episcleritis 
Scleritis 
Conjunctivitis 
Ophthalmologic 
Retinal vascular disease 
Iron deficiency anemia Hematologic 
Autoimmune hemolytic anemia 
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System Manifestations 
Anemia of chronic disease 
Leukocytosis or thrombocytosis 
Leukopenia or thrombocytopenia 
Hypercoagulable state 
Coagulation abnormalities 
Steatosis 
Primary sclerosing cholangitis 
Pericholangitis 
Cholangiocarcinoma 
Hepatobiliary 
Autoimmune hepatitis 
 
Laboratory Findings  
Laboratory findings in UC are nonspecific and reflect the severity of the 
underlying disease. Patients with limited distal disease often pass visible blood in the 
stool, but the amount of blood loss typically is small and anemia, if present, is mild. 
Patients with active extensive disease or severe distal disease may have anemia, 
leukocytosis and thrombocytosis, which reflect active disease. In contrast, patients with 
quiescent UC typically manifest no laboratory abnormalities. Iron deficiency anemia may 
be present because of chronic blood loss. Anemia also may be present secondary to bone 
marrow suppression resulting from chronic inflammation or medications, such as 
azathioprine, 6-mercaptopurine (6-MP), and sulfasalazine. 
Mild or moderate attacks rarely are associated with any biochemical disturbance. 
Hypokalemia, metabolic alkalosis, and elevated serum creatinine may be present in 
severe flares of UC, reflecting volume depletion. Hypoalbuminemia may be seen with 
both acute and chronic disease. Minor elevations in serum levels of aspartate 
 23
aminotransferase or alkaline phosphatase also are frequently associated with severe 
disease; these abnormalities probably reflect a combination of fatty liver, sepsis, and poor 
nutrition.  
Serum inflammatory markers including erythrocyte sedimentation rate (ESR) and 
C-reactive protein (CRP) may be elevated in active disease. Measuring them may be 
useful to assess disease activity in individual patients, particularly if these values are 
normal during periods of inactive disease.  
Diagnosis  
The diagnosis relies on a combination of compatible clinical features, endoscopic 
appearances, and histologic findings.  
Endoscopy  
The hallmark of UC is symmetrical and continuous inflammation that begins in 
the rectum and extends proximally without interruption for the entire extent of disease. 
The earliest endoscopic sign of UC is a decrease or loss of the normal vascular pattern, 
with erythema and edema of the mucosa. Distortion or loss of vascular markings may be 
the only endoscopic evidence of UC in patients with quiescent disease. As the disease 
progresses, the mucosa becomes granular and friable. With more severe inflammation, 
the mucosa may be covered by yellow-brown mucopurulent exudates associated with 
mucosal ulcerations. 
 In UC, mucosal ulcerations occur in areas of inflammation; vary in size from a 
few millimeters to several centimeters; and may be punctate, annular, linear, or 
serpiginous. Finally, severe UC is associated with mucosa that bleeds spontaneously, and 
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there may be extensive areas of denuded mucosa from severe mucosal ulcerations with 
diffuse colitis.  
Pseudopolyps may be seen in patients with long standing UC which indicate  in 
active disease and result from inflamed, regenerating epithelium that is interposed among 
ulcerations.  
There is a loss of the normal colonic architecture with long-standing inflammation 
that is characterized by muscular hypertrophy, loss of the normal haustral fold pattern, 
decreased luminal diameter, and shortening of the colon; a resultant featureless 
appearance of the colon in chronic UC gives rise to the so-called lead pipe seen on 
barium enema examination.  
Radiology  
 Plain abdominal radiograph: gives information about  
 1) Thickening of the colonic wall 
 2) Extent of the disease 
 3) Complications like toxic mega colon and perforation 
Barium studies: 
Endoscopy replaced barium studies in the care of patients with UC.  
Barium studies of the colon still useful in  
1) The evaluation of colonic strictures - location, length, and diameter and 
 allows visualization of the entire colon when strictures preclude 
 advancement of the colonoscope.  
2) Upper gastrointestinal barium study and small bowel follow-through to 
 exclude Crohn's disease.  
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3) Radilogical changes in ulcerative colitis:  
4) The earliest radiologic change of UC seen on barium studies is fine 
 mucosal granularity 
5) The mucosal line becomes irregular and becomes thickened and irregular, 
 and superficial ulcers are seen 
6)  Deep ulceration can appear as “collar-stud” or “collar-button” ulcers in 
 tangent, which indicates that the ulceration has extended through the 
 mucosa to the muscularis propria 
7) Loss of haustrations  in patients with long-standing disease  
8) Other chronic changes are shortening of the colon and widening of the 
 presacral space as seen on a lateral film of the rectum. 
9) Pseudopolyps may be present and often are filiform. In the presence of 
 active changes, these pseudopolypoid changes can resemble a cobblestone 
 pattern  
Assessment of Disease Activity 
A numerical disease activity instrument that is more useful for patients with 
limited disease .This index is the sum of scores from four components: stool frequency, 
rectal bleeding, sigmoidoscopic findings, and physician's global assessment. This disease 
activity index ranges from 0 to 12, with the higher total scores representing more severe 
disease. In general, a patient is considered to be in remission if the Ulcerative Colitis 
Disease Activity Index score is equal or less than 2 and to have severe disease if the score 
is greater than 10. Clinical response generally is accepted to be reflected by a decrease by 
3 points from the patient's initial baseline score.  
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Ulcerative Colitis Disease Activity Index  
Variable/Score Criteria 
Stool Frequency 
0 Normal 
1 1-2 stools/day > normal 
2 3-4 stools/day > normal 
3 >4 stools/day > normal 
Rectal Bleeding 
0 None 
1 Streaks of blood 
2 Obvious blood 
3 Mostly blood 
Mucosal Appearance 
0 Normal 
1 Mild friability 
2 Moderate friability 
3 Exudation, spontaneous bleeding
Physician Global Assessment 
0 Normal 
1 Mild 
2 Moderate 
3 Severe 
* Range: 0–12. 
 
SEO’S Activity Index:( 85) 
Seo etal studied Quantification of disease severity in 72 patients with ulcerative 
colitis, who had undergone total 85 clinical courses. They performed a multiple stepwise 
regression analysis, according to Truelove and Witts' classification, with disease severity 
as a dependent variable, and with 18 clinical, laboratory, and endoscopic parameters as 
independent variables. Results showed that disease severity in patients with ulcerative 
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colitis is significantly influenced by five factors, namely, bloody stool, bowel 
movements, erythrocyte sedimentation rate (ESR), hemoglobin (Hb), and serum albumin. 
The activity index (AI) developed for ulcerative colitis is expressed as follows: AI = 60 x 
blood stool + 13 x bowel movements + 0.5 x ESR - 4 x HB - 15 x albumin + 200. Index 
values below 150, values between 150 and 220, and values above 220 nearly 
corresponded to mild, moderate, and severe disease, respectively, in Truelove and Witts' 
classification. 
MEDICAL THERAPY: 
The goals of therapy of UC are 
  (1) To induce remission 
(2)  To maintain remission 
(3)  To maintain adequate nutrition 
(4)  To decrease disease- and treatment-related complications 
(5)  To improve the quality of life. The current management strategy focuses 
on using appropriate medical therapy and optimizing timing of surgery. 
Current therapeutic strategies can be classified broadly based on disease activity 
into those that treat active disease (induction therapy) and those that prevent recurrence 
of disease once remission is achieved (maintenance therapy)  
The extent of disease in any given patient is an important consideration to help 
determine the route of administration of medication. Enema preparations may be used 
alone or in combination with systemic therapy for patients with left-sided disease or 
disease distal to splenic flexure. Proctitis or disease limited to the rectum may be treated 
with suppositories or foam preparations. Other important factors to consider are prior 
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response to or side effects from a specific medication and patient compliance. These 
factors might favor or preclude the use of a specific agent. 
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Table – 1.Induction Therapy for Ulcerative Colitis Depending on Disease Severity  
Mild disease Moderate disease Severe disease 
 
 
 
5-aminosalicylates  
     Topical (distal colitis) 
     Orgal (distal/extensive      
     colitis) 
     Combination 
5-aminosalicylates 
     Topical (distal colitis) 
     Oral (distal/extensive      
     colitis) 
     Combination 
Glucocorticoids 
     Topical (distal) 
     Oral (distal/extensive) 
     Combination 
 
Azathioprine or 6-    
    mercaptopurine 
 
IV 
glucocorticoids 
 
 
IV cyclosporine 
 
 
 
IV infliximab 
IV, intravenous. 
 
Table -2   -- Maintenance Therapy for Ulcerative Colitis  
Preparation Type 
TopicalDistal  
5-Aminosalicylates Oral (distal/extensive) 
Azathioprine or 6-mercaptopurine Oral for severe diseases and steroid sparing. 
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DEFENSINS 
  Defensins are small cationic antimicrobial peptides that form an important part of 
the innate immune system and protect the intestinal mucosa against bacterial infection. 86 
and play an important role in host immune system to some infectious diseases, immune 
diseases and skin disease Hexamers of defensins create voltage-dependent ion-channels 
in the target cell membrane causing permeabilization and ultimately, cell death 
It has been suggested that deficient defensin expression may underlie the chronic 
inflammation of Crohn’s disease.  The DNA copy number of the β-defensin gene cluster 
on chromosome 8p23.1 is highly polymorphic within the healthy population, which 
suggests that the defective β -defensin induction in colonic CD could be due to low β -
defensin-gene copy number (89). 
  Defensins’ are two types alpha(α) and Beta(β)-defensin.  The α - defensins are 
the first group discovered and until now six human α-defensins were detected (90).  α-
defensins are strongly expressed in neutrophils and are also present in certain epithelia, 
such as gut wall, endocervix and vagina.  β -defensins are expressed in a variety of 
epithelia of the respiratory air ways (91).  α - defensins are closely related to the β -
defensins, differing in the spacing pattern of conserved cytosine residues and the linkage 
arrangements of the distal fide bands.  These genes have been mapped to 8p22-p23 
(Figure 1). Several types of beta–defensin are noted. DEBF4 is effective against 
Escherichia coli and prevention of Pseudomonas aeruginosa infection at micromolar 
concentration.  The anti microbial properties of DEFB4 were expressed in leukocytes and 
acts as a chemokine for cells of the adaptive immune response (102).Recent studies 
identified that the genes coding for human β -defensin 2 (HBD-2 or DEFB4), human β -
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defensin 3 (DEFB103) and human β defensin 4 (DEBF104) showed variation in copy 
numbers.  In Crohn’s disease, reduced Paneth cell production of a-defensins in the ileum 
is considered to be a significant factor in pathogenesis of the disease. In ulcerative colitis, 
studies have shown that epithelial cells and plasma cells in the colon have increased 
expression of human β -defensin 2 (or DEFB4) mRNA. This increased expression of the 
defensins may be due to increased bacterial load in the lumen. Alternatively it may be 
genetically regulated, by the copy number polymorphisms of the DEFB4 gene.  This 
variation may have an impact on gene expression levels. There has been no study of copy 
number polymorphisms of DEFB4 and ulcerative colitis, so the present studies were 
designed to measure the DEFB4 gene copy numbers in patients with ulcerative colitis (116 
– 120) 
Figure1. Defensin genes. 
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AIMS OF THE STUDY 
 To perform a case control study in patients with ulcerative colitis and matched 
controls: 
1. To determine whether there are specific associations of ulcerative colitis with factors 
connected with childhood hygiene, and effect of appendectomy or tobacco usage on 
incidence of ulcerative colitis. 
2. To determine the frequency of DEFB4 gene copy number polymorphisms in patients 
with ulcerative colitis and matched control volunteers. Normally each individual has 
two copies of a gene. However, certain genes are present in multiple repeats, and this 
number varies between individuals. This is known as a copy number polymorphism. 
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MATERIALS 
SUBJECTS 
CASES: Confirmed cases of ulcerative colitis diagnosed by clinical history, 
colonoscopic findings and histology. The clinical history consisted of history of blood 
and mucus diarrhoea presently or in the past. Colonoscopic findings of presence of 
symmetrical and continuous inflammation that began in the rectum and extended 
proximally without interruption with features of loss of normal vascular pattern, erythema 
and edema of mucosa with or without granularity, friability with presence of yellow 
brown mucopurulent exudates associated with mucosal ulceration which can be punctate, 
annular, linear or serpigenous and +/- presence of pseudopolyps. Histology showing 
cryptitis or crypt abscesses and absence of granulomas. Histologically the disease was 
graded as quiescent, mild, moderate and severe depending on the activity.Quiescent 
colitis was characterized by presence of architectural alterations with or without the 
presence fibrosis with no features of neutrophils infiltration, no edema no ulcers. 
Mild, moderate, severe disease were divided depending on the  
1) Degree of neutrophil infiltration of the crypts and depth of mucosal infiltration 
2) Amount of mucin depletion 
3) Amount of edema and congestion with or without presence of the ulcers.  
Grade increases if the above features increase in severity.  
CONTROLS: Controls included patients with irritable bowel syndrome who were 
matched for age, sex and geographical region with no history of blood or mucus in stools 
and no family history of IBD. 
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METHODS 
 The study was designed as a prospective case control study. It was presented to 
the institutional review board and the protocol and the consent form were approved. 
All participants were investigated only as clinically indicated. In the case of 
patients with ulcerative colitis, this included colonoscopy and biopsy and tests to 
establish the general severity of the disease and complications. Informed written consent 
was obtained from all participants or the guardian. A detailed questionnaire including risk 
factors of ulcerative colitis was read out to the patients and controls and their responses 
were recorded in the form. All the responses were later entered in to a computer 
spreadsheet for analysis using a statistical program.    
Questions regarding risk factors concerned with hygiene were demarcated as 
during “childhood” and “current”.  The reason was to determine whether specific 
associations existed with childhood hygiene or with current state of hygiene. These 
included (1) residence in urban area (or) village, (2) history of intestinal parasitic 
infestation, (3) drinking water source for the household and (4) availability of toilets.  
Questionnaires also included a detailed evaluation of socioeconomic status based on the 
modified Kuppuswamy scale, a past history of appendicectomy, and a history of 
consumption of tobacco in any form. 
A 10ml sample of venous blood was drawn by me or by one of the laboratory co-
investigators into Vacutainers.  DNA was isolated from the whole blood and stored at -
20oC for copy number polymorphism analysis.  
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DNA Extraction and Polymorphic Analysis: 
DNA isolation from blood 
Materials required: 
1. EDTA coated vacutainer tube 
2. Centrifuge 
3. Plastic pasteur pipette (sterile) 
4. 15 ml self standing centrifuge tube (sterile) 
5. RBC lysis buffer 
6. WBC lysis buffer 
7. Proteinase K 
8. 10% SDS 
9. Saturated NaCl 
10. Absolute alcohol 
11. Eppendorf tubes (sterile) 
12. 70% ethanol 
13. TE buffer 
Reagent preparation: 
RBC lysis buffer: 
Dissolve 8.275 g of ammonium chloride and 1 g of potassium bicarbonate in 1 
liter of water. Check the pH and that should be 7.4. Sterilize the solution by autoclaving. 
Can be stored at room temperature for a period of 1 year. 
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WBC lysis buffer: 
Mix 25ml of 0.5 M EDTA and 2.19 g of NaCl in 250ml of water and adjust the 
pH to 8.0 and make up the volume to 500 ml with water. Sterilize by autoclaving. Can be 
stored at room temperature for 3 months. 
Tris-EDTA buffer (10 mM Tris & 0.1 mM EDTA): 
Mix 1 ml of 1 M Tris (pH 8.0) and 400µl of 0.25 M EDTA (pH 8.0) and make up 
the volume to 100 ml with water. Sterilize by autoclaving. Can be stored at room 
temperature for 1 year. 
10% SDS: 
Dissolve 10 g of SDS in 100 ml of water and heat the solution at 65° C to assist 
dissolution. Sterilization is not required. Can be stored at room temperature for 6 months. 
Proteinase K: 
Dissolve the lyophilized Proteinase K (Cat no.PK1, genei) in 10 ml of sterile 
water to obtain a concentration of 10mg/ml. Aliquot 500µl volume into Eppendorf tubes. 
Can be stored at –20° C for a long period. 
Saturated NaCl: 
Dissolve 36.05 g of NaCl in 100 ml of water and is saturated or 6M NaCl 
solution. Sterilize by autoclaving and store at room temperature for up to 1 year. 
(Note: Always use milliQ water for the reagents preparation) 
Procedure: 
1. Collect the blood in EDTA-coated vacutainer tube. 
2. Centrifuge the blood sample at 4000 rpm for 15 min. 
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3. Three layers will be visible: the top yellow layer is the plasma, the middle  white 
layer is the buffy coat and the bottom red is the erythrocytes. Carefully remove 
the plasma and discard it and collect the buffy coat in a fresh tube. 
4. Add ten volumes of RBC lysis buffer and incubate at room temperature for 10 
min. 
5. Then centrifuge the tube at 4000 rpm for 10 min. Discard the supernatant and a 
white pellet will be seen. 
6. Repeat the wash until a clear white pellet is obtained. 
7. Then to the pellet add 4.5 ml of WBC lysis buffer and make a homogenous 
solution. Add 250 µl of 10% SDS and 100 µl of Proteinase K and mix them well 
and incubate at 37° C for overnight or at 55° C for two hours. 
8. Check the lysis, if the lysis is not complete, then add 50 µl of Proteinase K and 
continue the digestion. 
9. If the lysis is complete, add 1.5 ml of saturated NaCl solution and mix well till the 
solution turns milky white. 
10. Centrifuge the solution at 4000 rpm for 15 min and collect the supernatant  in a 
fresh tube. 
11. To the supernatant add two volumes of absolute ethanol and mix gently, a  white 
thread like structure will appear and will reach the top of the solution. 
12. Collect the thread like structure in a fresh eppendorf tube containing 1ml of 70% 
ethanol, using a sterile pipet tip. 
13. Tap the tube well to remove the excess salt adhering to the precipitate. 
14. Remove the precipitate using a pipet tip and air-dry it. 
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15. When the precipitate turns transparent, transfer it into an eppendorf tube 
containing 200-300 µl of TE buffer. 
16. The DNA can be dissolved by incubating at 37° C for 2 hr or 65° C for 30  min. 
17. Store the DNA in deep freezer (-20 is adequate) for long-term storage or in the 
fridge for short term. 
COPY NUMBER POLYMORPHISM ANALYSIS 
DEBF4 copy number was assessed by quantitative real time polymerase chain 
reaction using SYBR Green method.  PCR was carried out on a Chromo4 (MJ Research, 
USA) thermal cycler equipped with a continuous fluorescence detector and the PCR 
protocol was an initial denaturation step for 1 min at 95° C followed by 40 cycles 
consisting of denaturation step for 30 sec at 94° C, annealing step for 30 sec at 58° C, and 
extension step for 30 sec at 72° C and plate read to acquire the fluorescence and  after 40 
cycles a final extension step of 72° C for 5 min. Melting curve analysis was carried out to 
check the specificity and single peak was used to confirm the specificity. Copy numbers 
were calculated by normalizing against a gene with stable copy number. Here, Albumin 
was used as reference gene due to its stable copy numbers.  Both DEFB4 and albumin 
were quantitated using specific primers forward: 5’- ctcacacagccctgaaaaca -3’, reverse: 
5’- accgtcactcagggaatgtc -3’ and forward: 5’- aggctctttttcctggcaat -3’, reverse: 5’- 
tgaaacacccctccataagc -3’ respectively, and the Ct values were used for copy number 
quantitation using the formula 2-∆Ct (∆Ct = DEFB4 Ct –AlbuminCt) (113) .  The CNP was 
calculated and comparison was made between case and controls.  
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MELTING CURVE 
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SAMPLE SIZE DETERMINATION:  
As there was no Indian data regarding the frequency of defensin copy number 
polymorphisms in the general population, we calculated sample size assuming arbitrary 
frequencies of 5% for the general population and 25% for patients with ulcerative colitis. 
We calculated that a sample size for this study of 59 cases and 59 controls would detect 
the above difference with a power of 80% and an alpha value of 0.05. Patients with 
irritable bowel syndrome or functional bowel disorder were chosen as the control subjects 
because by definition these patients do not have a structural disorder of the bowel, and 
they are drawn from the same population as the cases. 
STATISTICAL ANALYSIS:   
For a statistical analysis, we used the SPSS (version 11).  For each of the parameters that 
are included, percentages, relative risks and 95% confidence intervals were calculated 
between the cases and controls.  Significance of the associations was calculated using the 
Chi Square test or Fisher’s exact test and P value of less than 0.05 was considered to be 
of statistical significance. 
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RESULTS 
Demographic characteristics:   
Cases:  75 cases of chronic ulcerative colitis were included in this study with mean age 
being 37 years (range 15–70 years). 44 were male and 31 were female (Figure 4). They 
hailed from various states like Tamil Nadu, West Bengal, Jharkhand, Andhra Pradesh and 
others. Their body mass index mean (SD) was 20.7 (4.3). 
Controls: 75 age, sex and religion matched controls were studied for the epidemiological 
associations and for study of defensin gene copy number polymorphism. The mean age of 
controls was 38 years (range 18-66 yrs) of which 43 were male and 32 were female 
(Figure 3). Their state of origin corresponded to the cases.  Their body mass index was 
21.3 (4.8). 
Figure4
 
 
SEX DISTRIBUTION OF THE CASES
44
31
Males
Females
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Figure5
SEX DISTRIBUTION OF CONTROLS
43
32 Males
Females
 
 
Epidemiological associations and risk factors: 
a) Place of residence, domestic water supply, and toilet availability.  These are all 
factors that determine the level of domestic hygiene.  The increasing incidence of 
inflammatory bowel disease with modernization has been attributed to the way in which 
the intestinal immune system is conditioned, especially in childhood, and this is the 
reason why these parameters were analyzed. The results of this analysis are shown in 
Table 2.   
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TABLE- 2 
RISK 
FACTORS 
ULCERATIVE 
COLITIS 
CONTROLS RR 95% CI P 
Childhood 
Residence 
  Urban 
  Village 
 
 
31 
44 
 
 
30 
45 
 
 
1.05 
 
 
0.56 – 2.02 
 
 
1.00 
Current 
Residence 
  Urban 
  Village 
 
 
39 
36 
 
 
43 
32 
 
 
0.80 
 
 
0.42-1.53 
 
 
0.62 
Childhood 
Water source 
  Protected  
  Unprotected  
 
 
10 
65 
 
 
6 
69 
 
 
1.76 
 
 
0.608 -5.144 
 
 
0.42 
Current water 
source 
  Protected 
  Unprotected 
 
 
41 
34 
 
 
29 
46 
 
 
1.91 
 
 
0.998 – 
3.664 
 
 
0.07 
Childhood toilet 
  Closed 
  Open 
 
 
44 
31 
 
 
36 
39 
 
 
1.53 
 
 
0.806 – 
2.932 
 
 
0.252 
Current toilet 
  Closed 
  Open 
 
68 
7 
 
66 
9 
 
1.32 
 
 
0.46 – 3.76 
 
 
0.79 
 
* Fisher exact test was used to compare these dichotomous variables, none of the 
differences was statistically significant. 
 
In this study, we did not find any statistically significant association of birth place 
(village or town), place of current residence (town or village), having a closed toilet in 
the house, with the diagnosis of ulcerative colitis. The usage of protected water showed a 
trend towards significance (p = 0.07) indicating that there could be a possible association 
if we studied more cases and controls. The usage of protected water was associated with 
nearly 1.9 times (CI 0.99 – 3.67) increased risk of developing ulcerative colitis compared 
to controls.   
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b) Personal habits and diagnosis of ulcerative colitis: 
TABLE 3 
RISK FACTORS ULCERATIVE 
COLITIS 
CONTROLS RR 95% CC P 
Toothpaste use in childhood  
  Users 
  Non users 
 
 
 
38 
37 
 
 
 
31 
44 
 
 
 
1.45 
 
 
 
0.76 – 
2.78 
 
 
 
0.32 
Toothpaste usage in Current    
  Users 
  Non users 
 
 
 
72 
 3 
 
 
 
66 
9 
 
 
 
3.27 
 
 
 
0.85 -
12.6 
 
 
 
0.13 
Worm infestation in 
childhood  
  Present 
  Absent 
 
 
 
31 
44 
 
 
 
41 
34 
 
 
 
0.584 
 
 
 
0.30 – 
1.11 
 
 
 
0.071 
Exposure to Pets in 
childhood 
  Yes 
  No 
 
 
 
27 
48 
 
 
 
21 
54 
 
 
 
1.45 
 
 
 
0.72 – 
2.89 
 
 
 
0.38 
Exposure to Pets now 
  Yes 
  No 
 
 
14 
61 
 
 
9 
66 
 
 
1.68 
 
 
0.68 – 
4.17 
 
 
0.37 
Exposures to Cows / Poultry 
In childhood 
  Yes 
  No 
 
 
 
39 
36 
 
 
 
38 
37 
 
 
 
1.05 
 
 
 
0.56 – 
2.001 
 
 
 
1.00 
Exposures to Cows / Poultry 
Now 
  Yes 
  No 
 
 
17 
58 
 
 
13 
62 
 
 
1.39 
 
 
0.62 – 
3.13 
 
 
0.54 
Breast Fed 
  Yes 
  No 
 
72 
3 
 
73 
2 
 
0.65 
 
0.10 – 
4.05 
 
1.00 
Separate Bedroom in 
childhood 
  Yes 
  No 
 
 
12 
63 
 
 
3 
72 
 
 
4.571 
 
 
1.234 – 
16.935 
 
 
0.02 
In this study we also compared various other risk factors for development of ulcerative 
colitis like usage of toothpaste in childhood, pets in the household, cattle and poultry in 
 45
the household, having a separate bedroom in childhood and breast feeding in infancy 
between cases and controls.    
In this study we did not find any significant difference in any of these putative risk 
factors except that the availability of a separate bedroom for the person in childhood was 
significantly associated with ulcerative colitis, with a relative risk of 4 (CI 1.23 – 16.93) 
(P=0.02). A separate bedroom in childhood probably signifies higher socioeconomic 
status and may be a surrogate marker of higher hygiene status in childhood. 
Socio Economic Status: 
Socio economic status of the cases and controls was also calculated (current status) to 
assess whether it has any effect on incidence of ulcerative colitis and also to see if it is an 
indirect marker of sanitation and health. The modified Kuppuswamy scale has been in 
wide use since 2 decades, and this was used for calculation of social economic status of 
subjects in this study.  This scale is a composite score of per capita monthly income, 
education of head of family and profession of the head.  It gives maximum score of 29 
and lowest score of 3.  There was no significant difference in social or economic score. 
Table- 4. Socio-economic Status: 
 Cases Controls P-value 
Social Score 17.2 + 5.2 17.1 + 4.4 0.8 
Economic Score 5.6 + 2.2 5.7 + 1.9 0.7 
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Risk Factors Associated with Past Medical, Family and Personal 
History:   
In the past medical and surgical history, we collected the data regarding the history of 
appendectomy, diabetes mellitus, hypertension and other abdominal surgeries (Table 4). 
In the family history we collected history of inflammatory bowel disease and 
consanguinity (Table 5). In the personal history we obtained history regarding smoking 
habits, alcohol consumption (Table 6) and types of food consumed, vegetarian or non 
vegetarian (beef, fish, pork, meat) (Table 7). 
Table-5. Past Medical and Family History in Cases and Controls: 
RISK FACTORS ULCERATIVE 
COLITIS 
CONTROLS RR 95% CI P 
Appendiecectomy 
  Done 
  Not done 
 
 
1 
74 
 
 
3 
72 
 
 
0.32 
 
 
0.33 – 3.19 
 
 
0.62 
Had abdominal 
Surgery 
  Yes 
  No 
 
 
10 
65 
 
 
16 
59 
 
 
0.56 
 
 
0.23-1.34 
 
 
0.28 
Diabetes Mellitus 
  Present 
  Absent 
 
 
5 
70 
 
 
7 
68 
 
 
0.694 
 
 
0.21 – 2.29 
 
 
0.76 
Hypertension 
  Present 
  Absent 
 
 
5  
70 
 
 
4 
71 
 
 
1.27 
 
 
0.32 – 4.91 
 
 
1.00 
Family history of 
IBD 
  Present 
  Absent 
 
 
2 
73 
 
 
0 
 
 
 
2.027 
 
 
1.72 –  2.38 
 
 
0.248 
Consanguinity 
  Present 
  Absent 
 
8 
67 
 
8 
67 
 
1 
 
 
0.36 – 2.82 
 
1.00 
 
 47
Table-6. Personal Habits 
 ULCERATIVE 
COLITIS 
CONTROLS RR 95% CI P 
Present 
  Smokers 
  Non Smokers 
 
2 
73 
 
13 
62 
 
0.246 
 
0.67 – 2.90 
 
0.005 
Past 
  Smokers 
  Non smokers 
 
11 
64 
 
23 
52 
 
0.58 
 
0.35 – 0.97 
 
0.03 
Tobacco  
Chewing 
  Yes     
  No 
 
 
12 
63 
 
 
13 
62 
 
 
0.9 
 
 
0.38 - 2.14 
 
 
1.00 
Alcohol 
  Yes 
  No 
 
12 
63 
 
14 
61 
 
 
1.2 
 
 
0.51 – 2.81 
 
 
0.69 
 
Table-7. Food Habits: 
 ULCERATIVE 
COLITIS 
CONTROLS RR 95% CC P 
Vegetarian 
  Yes 
  No 
 
13 
62 
 
5 
70 
 
2.93 
 
0.99 – 8.7 
 
0.07 
Beef 
  Yes 
  No 
 
17 
58 
 
9 
66 
 
0.465 
 
0.19 – 1.12 
 
0.13 
Fish 
  Yes     
  No 
 
62 
13 
 
67 
8 
 
1.7 
 
0.68 – 4.52 
 
 
0.34 
 
Pork 
  Yes 
  No 
 
4 
71 
 
2 
73 
 
0.486 
 
 
0.86 – 2.74 
 
0.68 
Meat 
  Yes 
  No 
 
61 
14 
 
65 
10 
 
1.49 
 
 
0.61 – 3.60 
 
0.5 
 
A history of current cigarette smoking or past tobacco smoking were both 
protective against ulcerative colitis.  Current smoking reduced the relative risk of 
ulcerative colitis to 0.246 (P=0.005); i.e. smokers were four times less likely to develop 
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ulcerative colitis. Past smokers had a relative risk of developing ulcerative colitis of 0.58 
(P=0.03), indicating a protective effect of 42%. However, tobacco chewing did not show 
any significant association with ulcerative colitis.  Previous studies have shown that 
alcohol consumption, western type of diet consumption especially like ham, meat were 
associated with increased incidence and increased relapse of ulcerative colitis.  However, 
in this study, dietary factors did not appear to significantly influence the development of 
ulcerative colitis.  In this study, we did not get any significant family history of IBD or 
history of consanguinity in the cases or controls.   
CLINICAL FEATURES OF ULCERATIVE COLITIS 
PATIENTS: 
Table-8. Age of onset of the disease 
 
Age range of Incidence of 
cases 
 
Number of cases 
 
Percentage 
 
1 – 10 1 1.34 
11 – 20 8 10.67 
21 – 30 22 29.34 
31 – 40 28 37.34 
41 – 50 9 12 
51 – 60 6 8 
61 – 70 1 1.34 
 
The above table shows frequency of onset of ulcerative colitis at various ages.  
The above table shows that most of the cases were in middle age group that is mostly 3nd 
and 4rd decades (91, 92) with incidence rate of 50cases (66.68%).  It is keeping in line with 
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other studies in which incidence was in the same decade as mentioned above but the 
second peak which was mentioned in the 6th decade was not seen in our study (93). 
Table-9. Symptoms of ulcerative colitis patients: 
  
Number of Cases 
 
Percentage 
 
Abdominal Pain 54 73.3 
Diarrhoea 73 97.3 
Blood in stool 73 97.3 
Urgency 70 93.3 
Tenesmus 59 78.7 
Incontinence 44 58.7 
Tiredness 64 85.3 
Fever 21 28 
Loss of weight 58 77.3 
Arthritis 55 73.3 
 
Most common symptom in ulcerative colitis was diarrhea with blood and mucus, 
and stools associated with urgency.  These symptoms were present in 93 to 97% of the 
cases.  Other symptoms like abdominal pain, tenesmus were little less around 70 to 75% 
and fecal incontinence was present in 58% of the cases.  Arthritis was the only 
complication which was common extra intestinal manifestation in our study which was 
present around 73% of the cases.  The high incidence of arthritis and of fecal 
incontinence could be secondary to referral bias.   
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Table-10. Extent of colitis: 
 
Colon Extent 
 
Number of Cases 
 
Percentage 
Pan colitis 44 58.7 
Left sided colitis 17 22.7 
Proctitis 14 18.7 
 
Colonoscopically the ulcerative colitis was diagnosed by the presence of symmetrical and 
continuous inflammation that began in the rectum and extended proximally without 
interruption for entire extent of disease.  Other features were decrease or loss of normal 
vascular pattern with erythema, edema of mucosa, and presence of granularity, friability 
with or without yellow brown mucopurulent exudates associated with mucosal ulceration 
and presence of pseudopolyps in long standing cases. When the above features suggestive 
of ulcerative colitis were present beyond the splenic flexure, it was considered as pan 
ulcerative colitis and if present till splenic flexure, considered as left sided colitis.  If the 
above features were localized to the rectum it was considered as proctitis.  In this study, 
pan ulcerative colitis was seen in 44 cases (58.7%), left sided colitis in 17 cases (22.7%) 
and proctitis in 14 cases (18.7%).   
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Table- 11. Clinical course of the disease in ulcerative colitis patients: 
  
Number of Cases 
 
Percentage 
 
Intermittent flare with 
complete resolution 
 
 
42 
 
56 
 
Mostly continuous illness 
 
23 
 
30.7 
 
 
Asymptomatic after initial 
attack 
 
7 
 
9.3 
 
First Episode 
 
3 
 
4 
 Most of the cases included in this study were already on treatment instituted here 
or elsewhere.  During the study, only three cases presented for the first time.  As seen in 
Table 11, the majority of our patients, 56%, had intermittent flares of disease with 
complete remission between flares, which is also common presentation in other studies 
(94). Mostly continuous disease was seen in 30.7% cases.  Quiescent disease after the first 
attack was seen in 9.3% cases.   
Table  12. Grade of Ulcerative Colitis (Histology): 
 
Grade  
 
Number of Cases 
 
Percentage 
 
Mild 
 
19 
 
25.34 
 
Moderate 
 
43 
 
57.34 
 
 
Severe 
 
12 
 
16.00 
 
Quiescent 
 
1 
 
1.3 
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Table 13. Laboratory Parameters 
  
Mean + SD 
 
 
Hemoglobin g% 
 
10.9 + 2.3 
 
ESR mm/h 
 
41.8 + 28.19 
 
 
Albumin g% 
 
3.76 + 0.71 
 
 
 Most of our patients were on treatment by the time of presentation.  So, Hb, 
albumin and ESR were within the normal range.  Hb. is being 10.9 + 2.3gm%, albumin 
3.76 + 0.7 and ESR 41.8 + 28.1.  
The Ulcerative Colitis Disease Activity Index (UCDAI) is the sum of scores of 4 
components, stool frequency, rectal bleeding, sigmoidoscopic findings and physician’s 
global assessment.  This disease activity index ranges from 0 to 12 with a higher total 
score representing more severe disease. Disease activity index in our study was 7.11 + 
3.67 which indicates most of these patients had mild or moderate activity, most probably 
secondary to the treatment.   
The Seo’s disease activity index(94) was also used for quantification of the disease 
activity.  The activity index (AI) is calculated using the formula:AI =  
60 x bloody stool + 13 x bowel movements + 0.5 x ESR – 4 x Hb – 15 x Albumin + 200 
and the above values are graded as less than 150 as mild, 150 – 220 as moderate and 
greater than 220 as severe. 
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Table-14. Seo’s Activity Index 
 
Mild ( < 150) 
 
31 
 
41.34 
 
 
Moderate (150 – 220) 
 
 
27 
 
36.0 
 
Severe (> 220) 
 
17 
 
22.67 
 
 
In this study, around 40% patients had mild disease and 36% patients had moderate 
disease and around 22% patients had severe disease as per the Seo’s activity index which 
was in correlation with the ulcerative colitis activity index. 
Table -15. Treatment  
DRUG HISTORY NUMBER OF 
PATIENTS 
PERCENTAGE 
H/O PAST AMINO SALICYLATE 
CONSUMPTION 
 YES 
  NO 
 
 
55 
20 
 
 
73.3 
26.7 
PAST ORAL STEROID CONSUMPTION 
 YES 
 NO 
 
41 
34 
 
54.7 
45.3 
PAST RECTAL STEROID  USAGE 
  YES 
   NO 
 
20 
55 
 
26.7 
73.3 
PAST H/O IV STEROIDS 
  YES 
  NO 
 
9 
66 
 
12 
88 
PAST H/O IMMUNOSUPRESSION 
   YES 
    NO 
 
16 
59 
 
21.3 
78.6 
PRESENTLY ON SALICYLATES 
     YES 
     NO 
 
50 
25 
 
66.7 
33.3 
PRESENTLY ON STREOIDS 
   YES 
    NO 
 
21 
54 
 
28 
72 
PRESENTLY ON IMMUNOSUPPRESSION 
     YES 
      NO 
 
11 
64 
 
14.7 
85.3 
 
 54
 Most of the patients mostly on salicylates treatment is around 66.7% only few of 
them work on steroids 28% only few needed immunosuppresion that is around 14.7%.  
HUMAN BETA-DEFENSIN 2 COPY NUMBER 
POLYMORPHISMS 
The human beta-defensin gene 2 (also known as DEFB4) copy number 
polymorphism results are shown in the Figure 6. The majority of the subjects had less 
than 4 copies of DEFB4 gene but significant number of the cases had 4 or more copies 
when compared to controls which were statistically significant (p- 0.005). Subjects with 
defensin gene copy numbers > 4 had relative risk of 2.85 times to develop UC. Thus the 
presence of four or more copies of this gene may be one of the causes of the pathogenesis 
of the ulcerative colitis.   
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P=0.005for 4 or more gene copies UC Vs controls. Fisher exact test. 
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TABLE 16 
COPY NUMBER 
POLYMORPHISMS
CASES CONTROLS P value* RR OF CNP 
<4 60 59 
>4 26 7 
0.005 2.85(1.32– 6.16) 
*Fisher exact test 
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DISCUSSION 
 Ulcerative colitis is a disease which was described mostly in the developed 
countries.  There are only a few studies from developing countries like India regarding 
incidence of ulcerative colitis which was increasing in present days and to see the effect 
of hygiene on the incidence and course of IBD. A study from the Punjab showed that 
prevalence of UC was nearly similar in India and in Western countries (115). 
The hygiene hypothesis has been developed to indicate why certain immune 
diseases are increasing in the modern world. If ulcerative colitis is increasing in India, 
perhaps it could be due to recent changes in the social practices, diet patterns and hygiene 
in India. Therefore this was undertaken as a case-control study to examine the effect of 
these parameters on the diagnosis of ulcerative colitis. 
The incidence of the ulcerative colitis in our population was approximately in the 
same age group as described by Yang SK et al (93) and Probert C .S et al (94) dscribed in 
2000 and 1996 respectively, that incidence was common in the 2nd and 3rd decades.  As 
our study was done at a point of when patients presented to our institution but were 
notfollowed the 2nd peak as described by Yang SK et al was not observed.  Equal sex 
incidence in our study was almost keeping with the two other studies described above. 
 The body mass index of this study group was within the range as described by 
Kuganthosan.S. et al (97) and Jabpsen et al (98).  
Various studies examined factors like geographical factors, environmental factors, 
social status, and microbial agents in the pathogenesis of IBD.  Data supporting the 
involvement of each of these factors in predisposing to, triggering (or) modulating the 
cause (or) outcome of IBD vary from strong to tenuous. Data by  Silvio Danere et al (100), 
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AE. Gent et al (99) suggested that there was no effect of the environmental factors and 
childhood hygiene as the outcome of ulcerative colitis except that study by Gent et al 
found that usage of protected water in childhood was associated with increased incidence 
of the ulcerative colitis.  This may be due to immune conditioning of the gastrointestinal 
tract. 
In this study, we also found that there was no significant difference between the 
cases and controls in factors like childhood environmental conditions such as residence in 
village (or) urban area, usage of closed toilet (or) history of worm infestation.  Like the 
study by Gent et al who found that hot water taps were more common in houses of 
subjects with IBD, in this study also people who consumed protected water had a relative 
risk of 1.96 when compared to people not consuming the protected water and increased 
risk may be secondary to the immune condition of the GI tract by the GI infections. 
Parasitic helminths are powerful modulators of their host’s immune system.   It is 
suggested that the reduced exposure to helminths, due to better hygiene condition, may 
predispose to the development of IBD. Helminths can activate Th2-type immune 
responses and down regulate Th1-type response.  The latter are responsible for 
production of interferon-gamma-tumor necrosis factor-alpha release and promote 
interleutein-10 transforming growth factor-beta and regulatory T-cell production.  Thus 
helminths can prevent and reverse intestinal inflammation.(101) The study by Gyaenee et 
al (102) has showed that helminth infestation was protective.  In our study we found that 
worm infestation in childhood was reaching significance (P-0.07) but not completely 
significant as the history was taken depending on the ability of the patients to recall this. 
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Around 10 cases (13%) were not sure of the worm infestation in childhood, and these 
were considered as not having the infection. 
Tooth paste which contains micro particles could also serve as proxy measures of 
hygiene conditions (or) have an impact on the microbial flora of the gut. However 
observational studies did not show any association implicating tooth paste as an 
independent risk factor which was shown in our study also which was consistent with the 
study by Bussel M.G. Et al in 1998 (103). 
In our study we studied the relation of pets (or) exposure to partly which did not 
show any significance which was the same in other studies by Benotein et al in 2006 (104). 
Breast feeding appears to be protective and its effect on ulcerative colitis was 
evidenced by various studies and a meta-analysis was done by Klement E et al(105) in 
2004 which revealed odds ratio ranged from 0.56 to 0.77 depending on the quality of 
study.  Even in our study the odds ratio was 0.65 indicating that breast feeding was 
possibly associated with protection from the ulcerative colitis. 
Having a separate bedroom in childhood is the one factor in our study  highly 
significant with a p value  of 0.02 and relative risk of 4.57 (1.23-16.03) indicating that 
having a separate room from childhood indicating higher socio economic studies and also 
may  reflect various psychosocial effects. 
There was no difference in the socio economic status of the cases and controls.  
This difference was noted as against the other studies may be because our subjects 
presented to the tertiary hospital rather than being recruited from the community. 
Therefore referral bias could have affected the socio economic status of these individuals.  
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Human appendix has been considered as a vestigial remnant, many case control 
studies suggest that previous appendectomy is rare in ulcerative colitis. In the appendix of 
the ulcerative colitis patients, the CD4/CD8 ratio is significantly increased and the 
proportion of CD4 + CD69 + (early activation antigen) T cells, but not of CD4+HLA-
DR4 (mature activation antigen). T Cells is also significantly increased.  These findings 
suggest that the appendix may be primary site in development of ulcerative colitis (106).In 
our study we found that OR of 0.32 for not developing the ulcerative colitis (CI 0.3-3.19) 
but this was not statistically significant. It was a little high when compared to study by 
Desanssure petat (107) who found OR of 0.1 (95% CI 0.05-0.21) (107).  We did not find any 
much difference in the incidence of ulcerative colitis in patient has had previous abdomen 
surgeries between the cases and controls. 
We found that family history of IBD in the first degree relative had an increased 
risk by 2,   seen in 2 patients (2.06 of patients).  There are consistent with the study done 
by park JB et al in 2006 who studied in Korean population found to have incidence of 
ulcerative colitis was around (2.01%) (108). 
The relation between smoking and IBD is complex ulcerative colitis is largely a 
disease of non-smokers and former smokers Cigarette smoking may even result in a 
beneficial influence on the course of ulcerative colitis.  The potential mechanisms 
involved in this dual relationship include changes in hormonal and cellular immunity, 
cytokine and eicosanoid levels, gut motility, permeability, blood flow, colonic mucosa 
and oxygen free radicals.  Nicotine is assumed to be the active moiety (110).  A meta 
analysis of Mahid SS et al (109) found that current smoking had a protective effect on 
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development of ulcerative colitis when compared with controls withOR-0.58 (95%CI 
0.45-0.75). 
In one study we found that relative risk was increased 7 times (CI 1.67-35.2; P-
0.005) in nonsmoker when compared to present smokers.  We also found that past 
smokers were protected 2.58 times (95 % CI 1.14-5.76) when compared to non-smokers 
with P value of 0.03.  But we did not find any protective effect of tobacco chewing (or) 
alcohol consumption. 
Various studies were done in different geographic areas with various types of 
dietary habits and the results varied.  In our study there was significant association 
between the various types of food consumed with OR ranging from 0.486 for having pork 
to 2.93 being a vegetarian.  It appears that strict vegetarians were at a risk of 2.93 
compared to non-vegetarians although this did not reach statistical significance.  
Zuinbliene et al (111) also studied various dietary habits but were not able to establish any 
specific association with any food habits. 
Tables 17 and 18 show differences between the present study and one by Park et 
al (112).The difference in the extent of colitis, severity, between the park SH et al and our 
study may be because most of the patient who were included in there study were first 
diagnosed cases but in our study were mostly referred cases which did not respond to 
routine treatment or who had relapse so in our study we had patients mostly with 
pancolitis and mild to moderate in severity because of treatment. 
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Table 17 
Clinical features Park SH et al Out Study 
M : F 0.94 : 1 1.59 : 1 
Median Age 40 (12 – 72 yrs) 38 (15 – 20 yrs) 
Proctitis 134 pts (44.1%) 14 pts (18.7%) 
Left sided colitis 69 pts ( 22.7%) 17 pts (22.7%) 
Pan colitis 101 pts (33.2%) 44 pts (58.6%) 
Mild 149 pts (49%) 19 pts (25.34%) 
Moderate 125 pts (41.1%) 43 (57.34%) 
Severe 26 pts (86%) 12 (16%) 
Quiscent  -- 1 (1.3%) 
 
Table 18 
Clinical Course 
 
 
Park SH et al  Cases (percentage) 
First episode 100 % 3 ( 4%) 
Asymptomatic after initial 
attack 
97.4% 7 (9.3%) 
Mostly continuous illness - 23 (30%) 
Complete resolution  42 (56%) 
 
 Defensins are antimicrobial peptides produced by professional phagocytes, Paneth 
cells, and intestinal epithelial cells. Current data favor the hypothesis that defensins and 
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Paneth cells(114) may play important roles in the maintenance of intestinal immune 
homeostasis.(116) Rahaman et al(120) demonstrated that lamina propria in colon from UC 
patients, Crohn's colitis patients, and controls contain cells that express hBD-2. They 
proposed that plasma cells were 2-3 times more abundant in UC colon than in control 
colon and Crohn's colitis. Moreover, plasma cells in UC colon expressed hBD-3 and 
hBD-4 mRNA. Additionally, hBD-2 mRNA expression was demonstrated in 3 out of 4 
well-characterized plasma cell lines and they concluded that mature colonic plasma cells 
can express multiple β-defensins. In UC, defensin production by plasma cells is probably 
clinically relevant since plasma cells accumulate in large numbers between the distorted 
crypts and muscularis mucosa.(117) A study by Fellermann(119) who  tested the genome 
wide DNA copy number profiling by array-based comparative genomic hybridization and 
quantitative polymerase-chain-reaction analysis of the human β -defensin 2 (HBD-2) 
gene they that healthy individuals, as well as patients with ulcerative colitis, have a 
median of 4 (range 2-10) HBD-2 gene copies per genome. In a surgical cohort with ileal 
or colonic CD and in a second large cohort with inflammatory bowel diseases, those with 
ileal resections/disease exhibited a normal median HBD-2 copy number of 4, whereas 
those with colonic CD had a median of only 3 copies per genome (P=.008 for the surgical 
cohort; P=.032 for the second cohort). Individuals with < or = 3 copies have a 
significantly higher risk of developing colonic CD than did individuals with > or = 4 
copies (odds ratio 3.06; 95% confidence interval 1.46-6.45) and they concluded that a 
lower HBD-2 gene copy number in the β -defensin locus predisposes to colonic CD, most 
likely through diminished β -defensin expression.(118) In our study we tested the copy 
number polymorphism of the β-defensin gene–2  which showed that patients with  
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ulcerative colitis had copy numbers 4 and more compared to controls (RR – 2.85 , CI – 
1.32 -6.16 , p -0.005), this was consistent with the study by Fellerman. Probably the 
higher expression may be due to higher concentration of the plasma cells in the ulcerative 
colitis patients compared to controls as explained by Rahmann et al. In conclusion it 
indicates that DEFB-4 gene copy number is more in UC patients compared to healthy 
people. Since our study population was in low number may need large number to 
definitely conclude the excess expression of this gene polymorphism in ulcerative colitis.   
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CONCLUSIONS 
 
 
 This case control study compared cases with ulcerative colitis and controls with 
irritable bowel syndrome and came up with the following findings: 
1. UC patients had mean age of onset of disease in third and fourth decades with no sex 
predilection and well preserved body mass index. 
2. Among several risk factors concerned with domestic hygiene only usage of protected 
water, lack of parasitic infestation in childhood and having a separate bedroom 
appeared to have significant risk for development of the ulcerative colitis. 
3. Among the personal habits, present smokers and past smokers were protected from 
development of ulcerative colitis. 
4. There was no association of type of diet consumed and diagnosis of UC. 
5. Defensin gene DEFB-4 copy number polymorphism testing revealed that copy 
number polymorphism of 4 and >  4 were associated with ulcerative colitis 
6. Apart from the blood mixed stools, urgency was the common presentation. 
7. Arthritis was the most common extra intestinal manifestation of ulcerative colitis  
8. Most of the patients had intermittent flares with complete resolution between flares. 
9. Pancolitis with moderate severity was the common presentation 
10. Disease was well controlled by medications like salicylates and oral steroids as most 
of the patients had mild activity with well preserved hemoglobin and albumin. 
 
 
 65
SUMMARY 
 This case control study of patients with ulcerative colitis seen in a tertiary referral 
hospital established that patients had onset of disease mostly in third and fourth decade of 
life, commonly had intermittent flares of disease, and usually had pancolitis and disease 
of moderate severity. Factors that were associated with a diagnosis of ulcerative colitis 
included consumption of protected water in childhood, having a separate bed room in 
childhood and absence of intestinal parasite infection in childhood. Socio economic 
status, type of food consumed and birth or residence in a village were not associated with 
the disease. Smoking, either current or past, was generally protective. Of interest, copy 
numbers of the human beta-defensin 2 (DEFB4) gene were higher in cases of ulcerative 
colitis (> 4) compared to controls. This could be important in the pathogenesis of 
ulcerative colitis.  
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APPENDIX - I 
 
PROFORMA FOR ULCERATIVE COLITIS 
 
Patients name        Hospital No. 
 
Contact Address 
 
 
Age in years   Sex  Male / Female       State of 
Origin 
 
 
Weight (Kg.)   Height (Cm)    Body Mass  
 
Index 
 
 
Epidemoligical information: 
 
At present where do you live?     Urban (1) / Village (2) 
 
When you were born, where did your mother live? Urban (1) / Village (2) 
 
Do you remember passing worms in your stool as a child?    Yes (1) / No (2)       
 
Did you use filtered or boiled water for drinking as a child? .   Yes (1) / No (2)   
 
Do you use filtered or boiled water for drinking currently?  Yes (1) / No (2)   
 
Did you have tap water in your home as a child?  Yes (1) / No (2)   
 
Do you currently have running tap water in your house? Yes (1) / No (2)           
 
Did you ever have a home with a closed toilet system  
when you were a child?     Yes (1) / No (2)   
 
Do you currently have a closed toilet system at home? Yes (1) / No (2)   
 
Usage of tooth paste for cleaning teeth as a child    Yes (1) / No (2) 
 
What do you use for cleaning teeth now? Toothpaste             Yes (1) / No (2) 
 
Did you sleep alone in a separate room as a child?  Yes (1) / No (2)                     
 
Did you keep pets at home as a child?      Yes (1) / No (2)                     
 
 
 
Do you keep pets at home now?     Yes (1) / No (2)                     
 
 Were there cows, buffaloes, goats, or poultry in your  
house or yard as a child?    Yes (1) / No (2)                  
 
Were there cows, buffaloes, goats, or poultry in your  
house or workplace now?    Yes (1) / No (2)    
 
 Were you breast fed?       Yes (1) / No (2)         
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 Socio economic status: (modified Kuppuswamy scale)    
 
A.  Social Score:- 
    a.  House      b.  No house  c. Katcha House    d. Mixed House  
   e. Pucca House f.  Mansion 
 
B. Material possessions (tick all applicable) 
 
Score:  Criteria  Article No.              Final score 
 
0.  None              1 Cycle                  1.  Radio     
 
Furniture more than 3 pieces 
 
Electrical fittings;          Bullock Cart           
 
Sewing Machine                 Well 
 
Motor cycle/moped/scooter         Improved agricultural 
implements 
 
TV/Tape/VCR                           Vessels in brass  More  
      than 5 
 
C. Education (mark highest score in household)  
 
Illiterate    0         Can read only       Can read and write        
 
Primary (Grade 1-5)      Middle School  (grade 6-8)      
 
High School (grade 6-8)    High Schoo (grade 9-10)         
 
Higher Secondary  (11-12)    Above 12th grade       . 
 
Total social score (A+B+C) 
.   
 
 
Economic Score: 
 
A) Occupation: mark only highest score for household:- 
 
Labour (Agri/unskilled labourer)           Labour (skilled)           
 
Small business and trader                  Independent professions      
 
Cultivator owner/tenant/landowner      Service (Govt./Private/Ex Service     
 
b) No of persons employed:      
 
 
 Total Economic score = (A+B) 
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Patient History:- 
 
At what age did symptoms appear? 
 
Have you ever had the following symptoms in relation to your illness? 
 
Abdominal pain        Yes (1) / No (2) 
Diarrhoea        Yes (1) / No (2) 
Blood in stool       Yes (1) / No (2) 
 
 
 
Past Medical History 
 
Diabetis Mellitus                           Yes (1) / No (2) 
Hypertension       Yes (1) / No (2) 
 
 
Past Surgical history 
 
Have you had appendicectomy      Yes (1) / No (2) 
History of any abdominal surgery           Yes (1) / No (2) 
 
Family History: 
 
 Has any member of your family been ever diagnosed to have?  IBD /Chronic 
diarrhea      
 
Personal habits: 
   
Do you current smoke cigarettes / beedis?    Yes (2)  / No (1) 
 
In the past id you smoke cigarettes/ beedis?    Yes (2) / No (1) 
 
Do you chew tobacco alone or with pan?    Yes (1) / No (2) 
 
Do you take alcoholic drinks?      Yes (2) /No (1) 
 
Dietary History: 
 
Are you a strict vegetarian                             Yes (1) / No (2) 
 
Do you consume beef      Yes (2) / No (1) 
 
Do you consume fish                                        Yes (2) / No (1) 
 
Do you consume pork                   Yes (2) / No (1) 
 
Do you consume meat                               Yes (2) / No (1) 
 
Complications: 
 
Have you ever had painful joint swellings          Yes (1) / No (2)                                   
 
Have you had chronic low back pain                  Yes (1) / No (2)          
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Medical treatment 
 
Have you ever used aminosalicylates in the past?   Yes (1) / No (2) 
 
Have you ever used oral steroids in the past                 Yes (1) / No (2) 
 
Have you ever used rectal steroids in the past          Yes (1) / No (2) 
 
Have you ever used IV steroids in the past                Yes (1) / No (2) 
 
Have you ever used azathioprine/other immuno 
       Suppressants in the past                                         Yes (1) / No (2)  
Are you currently using aminosalicylates                        Yes (1) / No (2)   
Are you currently using steroids (any form)         Yes (1) / No (2)  
Are you currently using azathioprine/ 
       Immuno-suppressants             Yes (1) / No (2) 
 
Chinical course : 1.Intermittent flares with complete resolution in between 
                                2. Mostly continuous illness 
                                3. Asymptomatic after initial attack 
                                4. First episode 
                                    
Disease extent:     1. Pancolitis   2. Extensive colitis  3. Left sided colitis   
 
            4.Proctitis 
 
Colonoscopy report 
 
Biopsy report 
 
Barium meal or CT report 
 
Laboratory findings 
 
            Test                            date                        report 
 
             Hb (g/Dl) 
         ESR (mm/h) 
                   S. Albumin 
                   Blood for genetic Studies 
 
          
Clinical activity index 
 
Symptom    Score   Symptom                           Score 
 
Diarrhea  (no. of daily stools                     Nocturnal diarrhea 
                0-2                                                                   No                                0 
                3-6                                                                  Yes                               1 
                7-9                                                     Fecal incontinence 
                10 or more                                                     No                                  0 
 
Visible blood in stool % of movement: 
                    0                                           0        Add pain/cramping 
                  Less than 50                          1                  None                               0 
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                  More than 50                         2                  Mild                        1 
                  100                                        3                 Moderate                          2 
 
 
 
   General wellbeing   
 
                 Perfect         0        Abdominal tenderness. 
                 Very good                                1                    None                            0 
                 Good                                       2                    Mild/localized          1  
                 Average                                   3                    Mild to mod/diffuse       2 
                 Poor                                   4                    Severe or rebound       3 
 
Need for antidiarrheal drugs     Total score 
 
               No                                             0  
               Yes               1 
 
 
See Disease Activity Index for UC 
 
Symptom                                           Score                   Weighting      Final score 
 
Bloody stool           x 60 
          Little or none                                0 
          Present                                        1                         
 
Bowel movements per day                                                        x 13 
< 4        1  
5-8                                          2 
> 8                                          3 
ESR (mm/h)                                                                                   x 0.5 
Hemoglobin (g/dl)                       x -4 
Albumin (g/dl)                                                                                 x-15 
Constant                                                                                         200 
          
Total score 
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Consent Form 
            
Dr. E.Umakanth ; Department of  Gastrointestinal sciences, CMC. Vellore is 
currently carrying out genetic analysis of patients suffering from Ulcerative colitis 
or IBS persons as controls. 
    
This document certifies that I _____________   have voluntarily accepted to 
participate in this study without any force from the investigators and am willing to 
give 10 ml of my blood for the same. I have been assured that the information 
generated from these tests is purely for scientific research and the results will be 
kept confidential. 
 
 
Signature of Participant                                                 Signature of Doctor 
 
Name of Participant      Date                             
   
 
 
